Fundamentals - AlphaKey Financial

Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

GMAB.US - Current Price

$33.95

Company Information

▼

Company Name

Genmab AS

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

ISIN: US3723032062

CIK: 0001434265

CUSIP: 372303206

Currency: USD

Full Time Employees: 2,681

Phone: 45 70 20 27 28

Website: https://www.genmab.com

Fiscal Year End: December

IPO Date: Jun 01, 2009

Description:

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Address:

Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500

Directors & Officers

▼

Name	Title	Year Born
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, President & CEO	1961
Mr. Rayne Waller	Executive VP & Chief Technical Operations Officer	1968
Mr. Christopher Cozic	Executive VP & Chief People Officer	1978
Dr. Martine J. van Vugt Ph.D.	Executive VP & Chief Strategy Officer	1971
Mr. Martin Schultz	Senior Director, Head of Development Business Partnership & Strategy and Director	1975
Dr. Judith V. Klimovsky M.D.	Executive VP & Chief Development Officer	1958
Dr. Tahamtan Ahmadi M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Experimental Medicines	1972
Dr. Mijke Zachariasse Ph.D.	VP, Head of Antibody Research Materials & Director	1973
Mr. Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	1975
Mr. Brad Bailey	Executive VP & Chief Commercial Officer	1968

Shares Statistics

▼

Shares Outstanding: 615.99M

Shares Float: 60.85M

% Insiders: 0.00%

% Institutions: 1,029.10%

Short % Float: 1.89%

Valuation Metrics

▼

Enterprise Value: $17.45B

Trailing P/E: 14.89

Forward P/E: 12.66

Financial Highlights

▼

Market Cap: $21.05B

EBITDA: $1.47B

P/E Ratio: $14.89

PEG Ratio: $0.67

Book Value: $93.41

Earnings/Share: $2.28

Profit Margin: 41.17%

Operating Margin: 44.91%

ROA (TTM): 13.38%

ROE (TTM): 29.41%

Revenue (TTM): $3.85B

Revenue/Share (TTM): $6.13

Earnings Growth (YOY): 107.60%

Revenue Growth (YOY): 17.40%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼

Date	EPS Actual	EPS Estimate	Difference	Surprise %
Mar 31, 2026	0.00	0.31	N/A	-10,000.00%
Dec 31, 2025	N/A	0.42	N/A	N/A
Sep 30, 2025	0.65	0.45	N/A	4,444.44%
Jun 30, 2025	0.54	0.34	N/A	5,882.35%
Mar 31, 2025	0.31	0.20	N/A	5,500.00%
Dec 31, 2024	0.84	0.28	N/A	20,000.00%
Sep 30, 2024	0.29	0.33	N/A	-1,212.12%
Jun 30, 2024	0.32	0.32	N/A	0.00%
Mar 31, 2024	0.29	0.14	N/A	10,714.29%
Dec 31, 2023	0.14	0.30	N/A	-5,333.33%
Sep 30, 2023	0.46	0.31	N/A	4,838.71%
Jun 30, 2023	0.30	0.29	N/A	344.83%
Mar 31, 2023	0.05	0.15	N/A	-6,666.67%
Dec 31, 2022	0.13	0.33	N/A	-6,060.61%
Sep 30, 2022	0.53	0.20	N/A	16,500.00%
Jun 30, 2022	0.40	0.20	N/A	10,000.00%
Mar 31, 2022	0.10	0.19	N/A	-4,736.84%
Dec 31, 2021	0.17	5.30	N/A	-9,679.25%
Sep 30, 2021	0.21	0.13	N/A	5,969.58%
Jun 30, 2021	0.08	0.07	N/A	1,065.01%
Mar 31, 2021	0.27	0.23	N/A	1,739.13%
Dec 31, 2020	0.14	1.28	N/A	-8,906.25%
Sep 30, 2020	0.13	0.99	N/A	-8,686.87%
Jun 30, 2020	7.58	6.43	N/A	1,788.49%
Mar 31, 2020	0.30	0.29	N/A	344.83%
Dec 31, 2019	3.41	3.43	N/A	-58.31%
Sep 30, 2019	1.23	0.36	N/A	24,166.67%
Jun 30, 2019	0.20	0.27	N/A	-2,592.59%
Mar 31, 2019	0.02	N/A	N/A	N/A
Dec 31, 2018	0.20	N/A	N/A	N/A
Sep 30, 2018	0.04	N/A	N/A	N/A
Jun 30, 2018	0.07	N/A	N/A	N/A
Mar 31, 2018	0.05	N/A	N/A	N/A
Dec 31, 2017	0.21	N/A	N/A	N/A
Sep 30, 2017	0.00	N/A	N/A	N/A
Jun 30, 2017	0.08	N/A	N/A	N/A
Mar 31, 2017	0.00	N/A	N/A	N/A
Dec 31, 2016	0.04	N/A	N/A	N/A
Sep 30, 2016	0.05	N/A	N/A	N/A
Jun 30, 2016	0.46	N/A	N/A	N/A
Mar 31, 2016	0.41	N/A	N/A	N/A
Dec 31, 2015	-0.03	N/A	N/A	N/A
Sep 30, 2015	0.95	N/A	N/A	N/A
Jun 30, 2015	0.34	N/A	N/A	N/A
Mar 31, 2015	0.04	N/A	N/A	N/A
Dec 31, 2014	0.52	N/A	N/A	N/A
Sep 30, 2014	0.19	N/A	N/A	N/A
Jun 30, 2014	0.47	N/A	N/A	N/A
Mar 31, 2014	-0.08	N/A	N/A	N/A
Dec 31, 2013	0.32	N/A	N/A	N/A
Sep 30, 2013	0.21	N/A	N/A	N/A
Jun 30, 2013	0.02	N/A	N/A	N/A
Mar 31, 2013	-0.09	N/A	N/A	N/A
Dec 31, 2012	0.10	N/A	N/A	N/A
Sep 30, 2012	-0.06	N/A	N/A	N/A
Jun 30, 2012	-0.17	N/A	N/A	N/A
Mar 31, 2012	0.03	N/A	N/A	N/A
Dec 31, 2011	-0.25	N/A	N/A	N/A
Sep 30, 2011	-0.13	N/A	N/A	N/A
Jun 30, 2011	-0.03	N/A	N/A	N/A
Mar 31, 2011	-0.31	N/A	N/A	N/A
Dec 31, 2010	-0.43	N/A	N/A	N/A
Sep 30, 2010	-0.31	N/A	N/A	N/A
Jun 30, 2010	-0.03	N/A	N/A	N/A
Mar 31, 2010	-0.05	N/A	N/A	N/A
Dec 31, 2009	-0.16	N/A	N/A	N/A
Sep 30, 2009	-0.04	N/A	N/A	N/A
Jun 30, 2009	-0.05	N/A	N/A	N/A

Balance Sheet (Yearly)

▼

Date	Cash	Total Debt	Total Assets	Total Liabilities	Total Equity
2024-12-31	$9.86B	$N/A	$45.81B	$9.11B	$36.70B
2023-12-31	$14.87B	$N/A	$35.29B	$3.68B	$31.61B
2022-12-31	$9.89B	$N/A	$30.12B	$2.84B	$27.28B
2021-12-31	$8.96B	$N/A	$24.63B	$2.43B	$22.20B
2020-12-31	$7.26B	$N/A	$21.14B	$2.02B	$19.12B
2019-12-31	$3.55B	$N/A	$15.14B	$1.10B	$14.05B
2018-12-31	$532.91M	$N/A	$8.46B	$446.64M	$8.01B
2017-12-31	$1.35B	$N/A	$6.60B	$330.75M	$6.27B
2016-12-31	$307.02M	$N/A	$5.24B	$411.54M	$4.83B
2015-12-31	$873.99M	$N/A	$3.90B	$415.83M	$3.49B
2014-12-31	$359.09M	$N/A	$2.87B	$833.74M	$2.03B
2013-12-31	$168.14M	$N/A	$1.73B	$1.07B	$659.52M
2012-12-31	$66.99M	$N/A	$1.69B	$1.31B	$383.19M
2011-12-31	$65.20M	$N/A	$1.56B	$1.08B	$486.42M
2010-12-31	$100.95M	$N/A	$2.48B	$1.40B	$1.08B
2009-12-31	$460.74M	$N/A	$2.22B	$924.34M	$1.30B
2008-12-31	$70.01M	$N/A	$3.26B	$1.07B	$2.19B
2007-12-31	$131.75M	$N/A	$3.96B	$1.08B	$2.88B
2006-12-31	$429.08M	$N/A	$1.80B	$197.05M	$1.61B
2005-12-31	$381.35M	$N/A	$1.37B	$251.66M	$1.12B
2004-12-31	$419.57M	$N/A	$1.27B	$90.92M	$1.18B
2003-12-31	$308.92M	$N/A	$1.18B	$93.67M	$1.09B
2002-12-31	$252.95M	$N/A	$1.58B	$183.97M	$1.40B